|Bid||179.97 x 1000|
|Ask||181.59 x 1400|
|Day's Range||183.26 - 186.09|
|52 Week Range||156.03 - 220.82|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.34|
|Expense Ratio (net)||0.24%|
As January effect is expected to bring the bulls back in the market this year, top-ranked small-cap ETFs and stocks could be solid pure play choices.
The measure of optimism among U.S. small-business owners touched a record on highest capital spending since 2007 and all-time high hiring.
After a lackluster July, growth stocks seem to have regained their appeal this month. This is especially true given that the S&P 500 Growth Index is up 3.9% so far this month, outpacing the gain of 1.6% for the S&P 500 Value Index.
Some signs are emerging that trend could be ready to change, but for investors looking for out-performance with growth stocks, small-caps remain the place to be. Exchange traded funds, including the iShares Russell 2000 Growth ETF (IWO) and the iShares S&P Small-Cap 600 Growth ETF (IJT) are surging. Year-to-date, IJT, which tracks the S&P SmallCap 600(R) Growth Index, is up more than 13%.
While interest rates are climbing, growth stocks and small-caps are delivering impressive performances this year. The iShares Russell 2000 Growth ETF (IWO) marries those two concepts and that exchange traded fund is up nearly 10% year-to-date. The $10.97 billion IWO tracks the Russell 2000 Growth Index, the growth offshoot of the widely followed Russell 2000 Index.
The U.S. stock market has started to feel the heat of summer in some corners. While the S&P 500 and the Dow Jones Industrial Average have seen a summer lull so far, the Russell 2000 index and Nasdaq Composite index have been burning with impressive gains of 3.6% and 3.5%, respectively, over the past one month.Source: Shutterstock
Netflix’s (NFLX) net income has grown at a three-year and five-year average of 27.9% and 101.1%, respectively. The company’s pre-tax margin grew from 3.9% in 2013 to 4.2% in 2017. The stock prices have beaten the media-diversified industry in 2013, 2015, and 2017. The stock was beaten in 2014 and 2016 by the S&P 500. The market cap had gained 279% between 2013 and 2017.
MiMedx Group (MDXG) operates in the regenerative biomaterials segment. MiMedx is a leading global supplier of amniotic tissue products and has supplied over a million allografts in wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.
Cara Therapeutics’ (CARA) investigational drug candidate, CR845, is being developed for providing pain relief. Intravenous (or IV) CR845 has shown a pain relief and tolerability profile in three Phase 2 clinical trials in patients with acute postoperative pain. Cara Therapeutics has initiated a Phase 3 clinical trial program for IV CR845 for postoperative pain in patients undergoing a range of abdominal surgeries.